Bruce Booth, Director at Kymera Therapeutics, Inc. (KYMR), sold 31,283 shares at $108.28 ($3.4M) on 2026-06-29, disclosed to the SEC on 2026-06-30.
Scheduled sale ($3.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $108.28 | 10,658 | $1.2M | 33.7% |
| 2 | $108.28 | 1,688 | $183K | 5.3% |
| 3 | $109.75 | 1,239 | $136K | 4.0% |
| 4 | $109.75 | 7,833 | $860K | 25.1% |
| 5 | $110.67 | 1,199 | $133K | 3.9% |
| 6 | $110.67 | 7,602 |
| $841K |
| 24.6% |
| 7 | $111.20 | 157 | $17K | 0.5% |
| 8 | $111.20 | 907 | $101K | 2.9% |
| Total | $109.48 avg | 31,283 | $3.4M | 100% |
| Filing → |
| KYMR | SELL | 2026-06-25 | $34.8M | — | Filing → |
| KYMR | SELL | 2026-06-25 | $44.0M | — | Filing → |
| KYMR | SELL | 2026-06-22 | $45.3M | — | Filing → |